StreetInsider.com News Articles

Profusa signs term sheet to acquire diagnostics firm with $111M revenue

Mon, 27 Jul 2026 06:00:19 -0400

Profusa, Inc. (Nasdaq: PFSA) has signed a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company, according to a press release from the Berkeley, Calif.-based company.

The unnamed diagnostics company reported estimated 2025 net revenues of approximately $111 million, based on unaudited management information. It operates CLIA-certified and CAP/CLIA accredited national medical laboratories providing molecular diagnostic tests and toxicology testing, serving addiction treatment, pain management, and behavioral health providers.

If a definitive agreement is reached, Profusa would issue to the target company's stockholders shares of Profusa common stock equal to 19.99% of its then-outstanding common shares,

Profusa signs term sheet to acquire diagnostics firm with $111M revenue

Mon, 27 Jul 2026 06:00:19 -0400

If a definitive agreement is reached, Profusa would issue to the target company's stockholders shares of Profusa common stock equal to 19.99% of its then-outstanding common shares,

Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company

Mon, 27 Jul 2026 06:00:00 -0400

BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company (the "Dx Company"). Following the contemplated transaction, the combined company is expected to operate as a public diagnostics company with national CLIA-certified laboratories, recurring revenues from a diversified base of providers serving addiction treatment, pain management, and behavioral health. The Dx Company’s 2025 Net Revenues are estimated, based on unaudited management information, to be approximately $111 million.

Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company

Mon, 27 Jul 2026 06:00:00 -0400

Profusa executes 1-for-25 reverse stock split on Nasdaq

Thu, 02 Jul 2026 11:00:11 -0400

Profusa, Inc. (Nasdaq: PFSA), a digital health company based in Berkeley, California, announced a 1-for-25 reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on July 7, 2026.

The company filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of Delaware to complete the action. Profusa's common stock will begin trading on the Nasdaq Global Market on a post-split basis on July 7, 2026, retaining the ticker symbol "PFSA" but with a new CUSIP number 74319X 306.

Under the terms of the split, every 25 shares of common stock issued and

Profusa Announces 1-for-25 Reverse Stock Split

Thu, 02 Jul 2026 11:00:00 -0400

BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, today announced that it ﬁled an amendment to its amended and restated certiﬁcate of incorporation with the Secretary of State of the State of Delaware to eﬀect a one-for-twenty-five (1:25) reverse stock split of its common stock. The reverse stock split will take eﬀect at 12:01 am (Eastern Time) on July 7, 2026, and the Company’s common stock will open

Profusa Announces 1-for-25 Reverse Stock Split

Thu, 02 Jul 2026 11:00:00 -0400

Profusa shareholders approve acquisition and Nasdaq compliance measures

Wed, 24 Jun 2026 08:00:48 -0400

Profusa, Inc. (Nasdaq: PFSA) said its shareholders approved all proposals at the company's 2026 Annual Meeting of Shareholders held June 23, 2026, in Berkeley, California.

The approved measures include authorization for the company's planned acquisition of the PanOmics multi-omics diagnostics platform from BioInsights LLC, approval of debt conversion matters aimed at strengthening the balance sheet, and authorization for a reverse stock split if the board determines it necessary to maintain Nasdaq listing compliance.

Shareholders also approved the election of a director, an amendment to the company's equity incentive plan, and authority to adjourn the meeting if additional shareholder solicitation was needed.

"We are

Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

Wed, 24 Jun 2026 08:00:00 -0400

BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all proposals presented at the Company’s 2026 Annual Meeting of Shareholders held on June 23, 2026.

The approved proposals included authorization related to the Company's planned acquisition of the PanOmics™ multi-omics diagnostics platform from BioInsights LLC, approval of debt conversion-related matters intended to strengthen the Company's balance sheet, authorization for a reverse stock split if deemed necessary by the Board to support Nasdaq listing compliance efforts, the election of a director, an

Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts

Wed, 24 Jun 2026 08:00:00 -0400

Profusa submits response to European regulator for Lumee device review

Fri, 12 Jun 2026 08:00:19 -0400

Profusa Inc. (NASDAQ: PFSA) submitted a response package to European Notified Body GMED as part of the ongoing CE Mark review process for its Lumee Oxygen Platform, the company announced.

The submission follows the completion of Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED under the Medical Device Regulation conformity assessment process. The response package included updates to technical documentation, quality system evidence, clinical evaluation activities, and supporting validation information.

"Submitting our responses to GMED marks another meaningful milestone in the CE Mark review process," said Ben Hwang, Chairman and Chief Executive Officer of Profusa. "We

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Fri, 12 Jun 2026 08:00:00 -0400

BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee^® Oxygen Platform.

The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting

Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform

Fri, 12 Jun 2026 08:00:00 -0400

The response package included updates across multiple aspects of the MDR submission, including technical documentation, quality system evidence, clinical evaluation activities, and supporting

Profusa urges shareholders to vote for all proposals at annual meeting

Wed, 10 Jun 2026 08:02:37 -0400

Profusa Inc. (NASDAQ: PFSA) issued a letter to shareholders encouraging support for all proposals at its June 23, 2026 annual meeting. The digital health company's board of directors unanimously recommends voting for the proposals.

Chairman and Chief Executive Officer Ben Hwang stated the proposals are intended to support the company's efforts to maintain its Nasdaq listing, enable securities issuance for the previously announced PanOmics asset acquisition, satisfy Nasdaq shareholder approval requirements for financing arrangements, and provide flexibility for equity compensation programs.

The Berkeley, California-based company announced an agreement to acquire assets relating to the PanOmics Assay platform, which it expects to expand

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Wed, 10 Jun 2026 08:00:00 -0400

BERKELEY, CA, June 10, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a leading digital health company pioneering next-generation biosensing technologies, today issued the following letter from Chairman and Chief Executive Officer Ben Hwang, Ph.D., to shareholders in advance of the Company's 2026 Annual Meeting of Shareholders scheduled for June 23, 2026.

Dear Fellow Shareholders,

As we approach our 2026 Annual Meeting of Shareholders, I would like to personally thank you for your continued support of Profusa and our mission to transform healthcare through innovative diagnostic and health

Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting

Wed, 10 Jun 2026 08:00:00 -0400

Dear Fellow Shareholders,

Profusa transfers listing to Nasdaq Capital Market

Fri, 15 May 2026 07:31:43 -0400

Profusa Inc. (NASDAQ: PFSA) announced its listing transfer to the Nasdaq Capital Market, effective May 15, 2026. The digital health company develops technology for continuous monitoring of biochemistry.

The transfer represents the first step in a series of interim milestones established by the Nasdaq Hearings Panel to ensure continued compliance with bid price and stockholders' equity requirements for Capital Market listing.

Based in Berkeley, California, Profusa develops tissue-integrated sensors that detect and transmit medical-grade data. The company describes itself as being in the commercial stage and focuses on injectable biosensors and data platform technology for personal and medical applications.

The company stated the

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market.

The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders’ equity requirements for continued listing on the Capital Market tier.

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Fri, 15 May 2026 07:30:00 -0400

Peter O'Rourke joins Quantum Cyber board as independent director

Thu, 14 May 2026 08:02:55 -0400

Quantum Cyber N.V. (NASDAQ: QUCY) appointed Peter M. O'Rourke Sr. as an independent member of its board of directors, effective immediately, according to a company statement.

O'Rourke served as acting secretary of the U.S. Department of Veterans Affairs under the Trump administration in 2018, leading over 380,000 employees and overseeing a federal healthcare and benefits system with an annual budget exceeding $180 billion. He previously held roles as chief of staff and senior advisor to the secretary, where he worked on the VA Mission Act and helped establish the VA Office of Accountability and Whistleblower Protection.

The appointee is a U.S. military

Peter O'Rourke joins Quantum Cyber board as independent director

Thu, 14 May 2026 08:02:55 -0400

Quantum Cyber N.V. (NASDAQ: QUCY) appointed Peter M. O'Rourke Sr. as an independent member of its board of directors, effective immediately, according to a company statement.

The appointee is a U.S. military

Peter O'Rourke joins Quantum Cyber board as independent director

Thu, 14 May 2026 08:02:55 -0400

Quantum Cyber N.V. (NASDAQ: QUCY) appointed Peter M. O'Rourke Sr. as an independent member of its board of directors, effective immediately, according to a company statement.

The appointee is a U.S. military

Quantum Cyber names former VA Secretary O'Rourke to board

Thu, 14 May 2026 08:01:25 -0400

Quantum Cyber N.V. (NASDAQ: QUCY) appointed Peter M. O'Rourke Sr. as an independent member of its board of directors, effective immediately, according to a company statement.

O'Rourke served as Acting Secretary of the U.S. Department of Veterans Affairs under the Trump administration in 2018, where he led over 380,000 employees and helped oversee a federal healthcare and benefits system with an annual budget exceeding $180 billion. He previously served as Chief of Staff and Senior Advisor to the Secretary, where he worked on the VA Mission Act and helped establish the VA Office of Accountability and Whistleblower Protection.

O'Rourke is a military